Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
11,751,000 | 11,501,000 | 12,337,000 | 11,731,000 | 12,322,000 |
Cost of Goods Sold (COGS) incl. D&A |
4,120,000 | 4,077,000 | 4,112,000 | 4,037,000 | 4,108,000 |
COGS excluding D&A |
2,459,000 | 2,354,000 | 2,308,000 | 2,247,000 | 2,247,000 |
Depreciation & Amortization Expense |
1,661,000 | 1,723,000 | 1,804,000 | 1,790,000 | 1,861,000 |
Gross Income |
7,631,000 | 7,424,000 | 8,225,000 | 7,694,000 | 8,214,000 |
SG&A Expense |
5,591,000 | 4,920,000 | 5,182,000 | 4,831,000 | 6,380,000 |
Research & Development |
2,221,000 | 1,950,000 | 1,997,000 | 1,808,000 | 2,762,000 |
Other SG&A |
3,370,000 | 2,970,000 | 3,185,000 | 3,023,000 | 3,618,000 |
Other Operating Expense |
0 | 0 | 0 | 0 | -559,000 |
Unusual Expense |
514,000 | 227,000 | 95,000 | 568,000 | 876,000 |
Non Operating Income/Expense |
-289,000 | -86,000 | -314,000 | 222,000 | -2,000 |
Equity in Affiliates (Pretax) |
232,000 | 158,000 | 142,000 | 110,000 | 0 |
Interest Expense |
190,000 | 178,000 | 172,000 | 195,000 | 192,000 |
Gross Interest Expense |
190,000 | 178,000 | 172,000 | 195,000 | 192,000 |
Pretax Income |
1,334,000 | 2,218,000 | 2,680,000 | 2,507,000 | 1,323,000 |
Income Tax |
385,000 | 455,000 | 860,000 | 740,000 | 38,000 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 257,000 |
Consolidated Net Income |
950,000 | 1,763,000 | 1,819,000 | 1,767,000 | 1,540,000 |
Minority Interest Expense |
42,000 | 34,000 | 27,000 | 29,000 | 31,000 |
Net Income |
908,000 | 1,729,000 | 1,792,000 | 1,738,000 | 1,509,000 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
908,000 | 1,728,999 | 1,792,000 | 1,738,000 | 1,508,999 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
908,000 | 1,729,000 | 1,792,000 | 1,738,000 | 1,509,000 |
Operational EPS |
0.42 | 0.61 | 0.60 | 0.70 | 0.69 |
EPS (basic) |
0.30 | 0.57 | 0.59 | 0.57 | 0.50 |
EBITDA |
3,701,000 | 4,227,000 | 4,847,000 | 4,653,000 | 4,254,000 |
Depreciation & Amortization Expense |
1,661,000 | 1,723,000 | 1,804,000 | 1,790,000 | 1,861,000 |
Common Shares Outstanding |
3,026,666 | 3,079,000 | 3,072,000 | 3,043,000 | 3,094,000 |
Basic Shares Outstanding |
3,026,666 | 3,045,000 | 3,041,000 | 3,043,000 | 3,071,000 |
Diluted Shares Outstanding |
3,026,666 | 3,079,000 | 3,072,000 | 3,043,000 | 3,094,000 |
Diluted EPS after Extraordinary Items |
0.30 | 0.56 | 0.58 | 0.57 | 0.49 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
0.30 | 0.57 | 0.59 | 0.57 | 0.49 |
*Figures in thousands of U.S. Dollars except shares outstanding.
